Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Time to Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $21.01, but opened at $20.11. Ascentage Pharma Group International shares last traded at $20.70, with a volume of 606 shares traded.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. BTIG Research reiterated a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Monday, April 13th. China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $46.67.

Ascentage Pharma Group International Stock Down 4.1%

The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79. The firm has a 50-day moving average price of $23.39 and a two-hundred day moving average price of $26.07.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The company had revenue of $24.72 million during the quarter. On average, sell-side analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current year.

Institutional Trading of Ascentage Pharma Group International

Several institutional investors and hedge funds have recently made changes to their positions in the company. UBS Group AG raised its holdings in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares in the last quarter. XY Capital Ltd raised its holdings in shares of Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after acquiring an additional 12,530 shares in the last quarter. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International in the second quarter valued at about $391,000. Citadel Advisors LLC bought a new stake in shares of Ascentage Pharma Group International in the third quarter valued at about $383,000. Finally, ABC Arbitrage SA bought a new stake in shares of Ascentage Pharma Group International in the third quarter valued at about $204,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.